AN2 Therapeutics, Inc.

By person

18 insiders · 140 transactions

14.3×

Eric Easom holds 14.3 times base salary in stock. $8.64M of shares against $603.75K in salary for 2025.

Salary from the company's own proxy. The shares are what Eric Easom last reported holding, valued at $6.02, the price Common Stock was last bought or sold at on the open market here, on 9 Sep 2026.

Insider

Role

Bought

Sold

Net

Holding

Of company

Worth

Change

RA CAPITAL MANAGEMENT, L.P. entity

10% owner

$41.84M (10)

$3.81M (2)

+$38.04M

300,853

0.7973%

$1.81M

—

Readnour Robin Shane

Director

$2.71M (16)

$428.37K (12) scheduled

+$2.28M

1,267,709

3.36%

$7.64M

+1,559%

Zakrzewski Joseph S

Director

$27.85K (3)

$1.91M (1)

−$1.88M

145,538

0.3857%

$876.76K

−71.2%

Leonard Braden Michael

10% owner

$1.56M (1)

$3.09M (5)

−$1.53M

3,217,432

8.53%

$19.38M

−27.7%

Adjuvant Global Health Technology Fund, L.P. entity

10% owner

$2.50M (1)

$3.98M (20)

−$1.48M

2,373,500

6.29%

$14.30M

—

Aziz Kabeer

Director

$2.50M (1)

$3.98M (20)

−$1.48M

436,648

1.16%

$2.63M

—

Easom Eric

Chief Executive Officer

$114.41K (3)

$1.55M (23)

−$1.44M

1,434,396

3.80%

$8.64M

+30.4%

Krause Kevin Michael

Chief Strategy Officer

—

$201.33K (2) scheduled

−$201.33K

31,914

0.0846%

$192.26K

+1,567%

Eizen Joshua M

See Remarks

—

$65.94K (5)

−$65.94K

206,554

0.5474%

$1.24M

+941.4%

FitzPatrick Margaret M

Director

$21.74K (2)

—

+$21.74K

10,708

0.0284%

$64.51K

—

Chanda Sanjay

Chief Development Officer

—

$13.30K (3)

−$13.30K

118,823

0.3149%

$715.83K

+677.6%

Day Lucy

Chief Financial Officer

—

$12.85K (3)

−$12.85K

118,363

0.3137%

$713.05K

+553.0%

Prior Stephen David

Chief Strategy Officer

—

$10.10K (4)

−$10.10K

59,086

0.1566%

$355.95K

+95.5%

Williams Sarah Joanne

Principal Accounting Officer

—

$3.02K (3)

−$3.02K

66,311

0.1757%

$399.48K

+252.7%

Trenor Cameron C. III

Chief Medical Officer

—

116,667

0.3092%

$702.84K

—

Marks Gilbert Lynn

Director

—

81,873

0.2170%

$493.23K

+258.6%

Eckburg Paul

Chief Medical Officer

—

51,416

0.1363%

$309.75K

+140.1%

Martin Patricia A.

Director

—

18,863

0.0500%

$113.64K

—

Individual transactions

Insider

Date

Role

Action

Price

Amount

Readnour Robin Shane

9 Sep 2026

Director

Sold on a plan indirect

585

$6.02

$3.52K

Readnour Robin Shane

9 Sep 2026

Director

Sold on a plan indirect

523

$6.02

$3.15K

Readnour Robin Shane

8 Sep 2026

Director

Sold on a plan indirect

5,294

$6.02

$31.86K

Readnour Robin Shane

8 Sep 2026

Director

Sold on a plan indirect

4,725

$6.02

$28.44K

Readnour Robin Shane

3 Sep 2026

Director

Sold on a plan indirect

3,223

$6.07

$19.56K

Readnour Robin Shane

3 Sep 2026

Director

Sold on a plan indirect

2,877

$6.07

$17.46K

Readnour Robin Shane

17 Aug 2026

Director

Sold on a plan indirect

18,706

$6.01

$112.39K

Readnour Robin Shane

17 Aug 2026

Director

Sold on a plan indirect

16,696

$6.01

$100.31K

Readnour Robin Shane

12 Jan 2024

Director

Sold on a plan indirect

719

$21.91

$15.75K

Readnour Robin Shane

12 Jan 2024

Director

Sold on a plan indirect

706

$21.92

$15.48K

Readnour Robin Shane

10 Jan 2024

Director

Sold on a plan indirect

1,800

$21.92

$39.46K

Readnour Robin Shane

10 Jan 2024

Director

Sold on a plan indirect

1,869

$21.93

$40.99K

Easom Eric

2 Jan 2024

Chief Executive Officer

Sold on a plan

2,777

$20.09

$55.80K

Aziz Kabeer

14 Nov 2023

Director

Sold on a plan indirect

288

$16.15

$4.65K

Aziz Kabeer

14 Nov 2023

Director

Sold on a plan indirect

1,522

$16.15

$24.57K

Adjuvant Global Health Technology Fund, L.P.

14 Nov 2023

10% owner

Sold on a plan indirect

288

$16.15

$4.65K

Adjuvant Global Health Technology Fund, L.P.

14 Nov 2023

10% owner

Sold on a plan

1,522

$16.15

$24.57K

Show all 140 transactions →

By person

Individual transactions

What was left out